Ann Hepatobiliary Pancreat Surg.  2024 May;28(2):161-202. 10.14701/ahbps.23-170.

Practice guidelines for managing extrahepatic biliary tract cancers

• Kim HS
• Kang MJ
• Kang J
• Kim K
• Kim B
• Kim SH
• Kim SJ
• Kim YI
• Kim JY
• Kim JS
• Kim H
• Kim HJ
• Nahm JH
• Park WS
• Park E
• Park JK
• Park JM
• Song BJ
• Shin YC
• Ahn KS
• Woo SM
• Yu JI
• Yoo C
• Lee K
• Lee DH
• Lee MA
• Lee SE
• Lee IJ
• Lee H
• Im JH
• Jang KT
• Jang HY
• Jun SY
• Chon HJ
• Jung MK
• Chung YE
• Chong JU
• Cho E
• Chie EK
• Choi SB
• Choi SY
• Choi SJ
• Choi JY
• Choi HJ
• Hong SM
• Hong JH
• Hong TH
• Hwang SH
• Hwang IG
• Park JS

• KMID: 2555929
• DOI: http://doi.org/10.14701/ahbps.23-170

Abstract

Backgrounds/Aims
Reported incidence of extrahepatic bile duct cancer is higher in Asians than in Western populations. Korea, in particular, is one of the countries with the highest incidence rates of extrahepatic bile duct cancer in the world. Although research and innovative therapeutic modalities for extrahepatic bile duct cancer are emerging, clinical guidelines are currently unavailable in Korea. The Korean Society of Hepato-Biliary-Pancreatic Surgery in collaboration with related societies (Korean Pancreatic and Biliary Surgery Society, Korean Society of Abdominal Radiology, Korean Society of Medical Oncology, Korean Society of Radiation Oncology, Korean Society of Pathologists, and Korean Society of Nuclear Medicine) decided to establish clinical guideline for extrahepatic bile duct cancer in June 2021.
Methods
Contents of the guidelines were developed through subgroup meetings for each key question and a preliminary draft was finalized through a Clinical Guidelines Committee workshop.
Results
In November 2021, the finalized draft was presented for public scrutiny during a formal hearing.
Conclusions
The extrahepatic guideline committee believed that this guideline could be helpful in the treatment of patients.

Keyword

Extrahepatic; Bile duct cancer; Guidlines

Reference

References

1. Choi M, Kim NS, Sheen SS, Ki SM, Lee SJ, Kim JY. The status and dissemination plan of clinical practice guideline in Korea. NECA;2015.

2. Choi M, Kim NS, Jung Y, Lee SJ, Son SK, Lyu DH. Promoting the quality of medicine: based on clinical practice guidelines. NECA;2015.

3. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. 2010; Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ. 182:1045–1052. DOI: 10.1503/cmaj.091714. PMID: 20513780. PMCID: PMC2900328.

4. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. 2010; Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ. 182:E472–478. DOI: 10.1503/cmaj.091716. PMID: 20513779. PMCID: PMC2900368.

5. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. 2013; Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 66:408–414. DOI: 10.1016/j.jclinepi.2012.09.016. PMID: 23337781.

6. Scottish Intercollegiate Guidelines Network (Sign). SIGN 50: a guideline developer's handbook. SIGN;2014.

7. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach 2013. cited 2013 Oct. Available from: https://gdt.gradepro.org/app/handbook/handbook.html.

8. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. 2008; GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 336:924–926. DOI: 10.1136/bmj.39489.470347.AD. PMID: 18436948. PMCID: PMC2335261.

9. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. 2008; What is "quality of evidence" and why is it important to clinicians? BMJ. 336:995–998. DOI: 10.1136/bmj.39490.551019.BE. PMID: 18456631. PMCID: PMC2364804.

10. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. 2008; Going from evidence to recommendations. BMJ. 336:1049–1051. DOI: 10.1136/bmj.39493.646875.AE. PMID: 18467413. PMCID: PMC2376019.

11. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. 2008; Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 336:1106–1110. DOI: 10.1136/bmj.39500.677199.AE. PMID: 18483053. PMCID: PMC2386626.

12. Clayton RA, Clarke DL, Currie EJ, Madhavan KK, Parks RW, Garden OJ. 2003; Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy. Surgeon. 1:32–38. DOI: 10.1016/S1479-666X(03)80006-9. PMID: 15568422.

13. Scheuermann U, Widyaningsih R, Hoppe-Lotichius M, Heise M, Otto G. 2016; Detection of benign hilar bile duct stenoses - A retrospective analysis in 250 patients with suspicion of Klatskin tumour. Ann Med Surg (Lond). 8:43–49. DOI: 10.1016/j.amsu.2016.05.001. PMID: 27257485. PMCID: PMC4878841.

14. Dumonceau JM, Delhaye M, Charette N, Farina A. 2020; Challenging biliary strictures: pathophysiological features, differential diagnosis, diagnostic algorithms, and new clinically relevant biomarkers - part 1. Therap Adv Gastroenterol. 13:1756284820927292. DOI: 10.1177/1756284820927292. PMID: 32595761. PMCID: PMC7298429.

15. Shanmugarajah I, Solhaug M, Aslam O, Reiertsen O. 2017; Efficacy and safety assessment of ERCP in patients with malignant biliary obstruction. Acta Gastroenterol Belg. 80:487–491.

16. Akita M, Ajiki T, Matsumoto T, Shinozaki K, Goto T, Asari S, et al. 2017; Preoperative cholangitis affects survival outcome in patients with extrahepatic bile duct cancer. J Gastrointest Surg. 21:983–989. DOI: 10.1007/s11605-017-3388-z. PMID: 28290140.

17. Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. 2019; Surgery for cholangiocarcinoma. Liver Int. 39 Suppl 1:143–155. DOI: 10.1111/liv.14089. PMID: 30843343. PMCID: PMC6563077.

18. Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. 2015; Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 17:691–699. DOI: 10.1111/hpb.12450. PMID: 26172136. PMCID: PMC4527854.

19. Lau SH, Lau WY. 2012; Current therapy of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 11:12–17. DOI: 10.1016/S1499-3872(11)60119-7. PMID: 22251465.

20. Ishii Y, Sasaki T, Serikawa M, Kobayashi K, Kamigaki M, Minami T, et al. 2014; Characteristic features of cholangiocarcinoma complicating primary sclerosing cholangitis. Hepatogastroenterology. 61:567–573.

21. Kuzu UB, Ødemiş B, Suna N, Yıldız H, Parlak E, Dişibeyaz S, et al. 2016; The detection of cholangiocarcinoma in primary sclerosing cholangitis patients: single center experience. J Gastrointest Cancer. 47:8–14. DOI: 10.1007/s12029-015-9777-1. PMID: 26537791.

22. Hultcrantz R, Olsson R, Danielsson A, Järnerot G, Lööf L, Ryden BO, et al. 1999; A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol. 30:669–673. DOI: 10.1016/S0168-8278(99)80198-6. PMID: 10207809.

23. Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, et al. 1995; CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg. 1:94–98. DOI: 10.1002/lt.500010204. PMID: 9346547.

24. John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR. 2006; Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? Dig Surg. 23:319–324. DOI: 10.1159/000098014. PMID: 17170527.

25. Patel AH, Harnois DM, Klee GG, Larusso NF, Gores GJ. 2000; The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 95:204–207. DOI: 10.1111/j.1572-0241.2000.01685.x. PMID: 10638584.

26. Hu C, Zhang Y, Zhang M, Li T, Zheng X, Guo Q, et al. 2021; Exosomal Cripto-1 serves as a potential biomarker for perihilar cholangiocarcinoma. Front Oncol. 11:730615. DOI: 10.3389/fonc.2021.730615. PMID: 34434900. PMCID: PMC8380828.

27. Liang B, Zhong L, He Q, Wang S, Pan Z, Wang T, et al. 2015; Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit. 21:3555–3563. DOI: 10.12659/MSM.895040. PMID: 26576628. PMCID: PMC4655615.

28. Tshering G, Dorji PW, Chaijaroenkul W, Na-Bangchang K. 2018; Biomarkers for the diagnosis of cholangiocarcinoma: a systematic review. Am J Trop Med Hyg. 98:1788–1797. DOI: 10.4269/ajtmh.17-0879. PMID: 29637880. PMCID: PMC6086160.

29. Loosen SH, Roderburg C, Kauertz KL, Koch A, Vucur M, Schneider AT, et al. 2017; CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep. 7:16975. DOI: 10.1038/s41598-017-17175-7. PMID: 29208940. PMCID: PMC5717041.

30. Prachayakul V, Rugivarodom M, Nopjaroonsri P, Cheirsilpa K, Chang A, Kamolhan T, et al. 2022; Diagnostic power of DNA methylation markers suggestive of cholangiocarcinoma in ERCP-based brush cytology. Gastrointest Endosc. 95:123–130.e1. DOI: 10.1016/j.gie.2021.07.005. PMID: 34265285.

31. Leelawat K, Narong S, Wannaprasert J, Leelawat S. 2011; Serum NGAL to clinically distinguish cholangiocarcinoma from benign biliary tract diseases. Int J Hepatol. 2011:873548. DOI: 10.4061/2011/873548. PMID: 21994874. PMCID: PMC3170848.

32. Salem PES, Ghazala RA, El Gendi AM, Emara DM, Ahmed NM. 2020; The association between circulating MicroRNA-150 level and cholangiocarcinoma. J Clin Lab Anal. 34:e23397. DOI: 10.1002/jcla.23397. PMID: 33161598. PMCID: PMC7676191.

33. Gül-Utku Ø, Karatay E, Ergül B, Kisa Þ, Erdin Z, Oğuz D. The Role of Resolvin D1 in the differential diagnosis of the cholangiocarcinoma and benign biliary diseases. Clin Lab. 2020; 66:DOI: 10.7754/Clin.Lab.2020.200212.

34. Leelawat K, Narong S, Wannaprasert J, Ratanashu-Ek T. 2010; Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol. 16:4697–4703. DOI: 10.3748/wjg.v16.i37.4697. PMID: 20872971. PMCID: PMC2951521.

35. Wintachai P, Lim JQ, Techasen A, Lert-Itthiporn W, Kongpetch S, Loilome W, et al. 2021; Diagnostic and prognostic value of circulating cell-free dna for cholangiocarcinoma. Diagnostics (Basel). 11:999. DOI: 10.3390/diagnostics11060999. PMID: 34070951. PMCID: PMC8228499.

36. Silsirivanit A, Matsuda A, Kuno A, Tsuruno C, Uenoyama Y, Seubwai W, et al. 2020; Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma. Clin Chim Acta. 510:142–149. DOI: 10.1016/j.cca.2020.07.017. PMID: 32659223.

37. Yamaguchi T, Yokoyama Y, Ebata T, Matsuda A, Kuno A, Ikehara Y, et al. 2016; Verification of WFA-sialylated MUC1 as a sensitive biliary biomarker for human biliary tract cancer. Ann Surg Oncol. 23:671–677. DOI: 10.1245/s10434-015-4878-4. PMID: 26416714.

38. Tangkijvanich P, Thong-Ngam D, Theamboonlers A, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. 2004; Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology. 51:15–19.

39. Ke W, Zeng L, Hu Y, Chen S, Tian M, Hu Q. 2018; Detection of early-stage extrahepatic cholangiocarcinoma in patients with biliary strictures by soluble B7-H4 in the bile. Am J Cancer Res. 8:699–707.

40. Kato Y, Takahashi S, Gotohda N, Konishi M. 2016; prognostic impact of the initial postoperative CA19-9 level in patients with extrahepatic bile duct cancer. J Gastrointest Surg. 20:1435–1443. DOI: 10.1007/s11605-016-3180-5. PMID: 27250990.

41. Tella SH, Kommalapati A, Yadav S, Bergquist JR, Goyal G, Durgin L, et al. 2020; Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol. 46:789–795. DOI: 10.1016/j.ejso.2020.01.016. PMID: 31954549.

42. Xu S, Zhang XP, Zhao GD, Zhao ZM, Gao YX, Hu MG, et al. 2022; Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 29:1214–1225. DOI: 10.1002/jhbp.1058. PMID: 34676993.

43. Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, et al. 2010; Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res. 15:357–361. DOI: 10.1186/2047-783X-15-8-357. PMID: 20947473. PMCID: PMC3458701.

44. Padthaisong S, Thanee M, Namwat N, Phetcharaburanin J, Klanrit P, Khuntikeo N, et al. 2020; Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma. J Transl Med. 18:64. DOI: 10.1186/s12967-020-02243-w. PMID: 32039729. PMCID: PMC7008521.

45. Menzel J, Poremba C, Dietl KH, Domschke W. 2000; Preoperative diagnosis of bile duct strictures--comparison of intraductal ultrasonography with conventional endosonography. Scand J Gastroenterol. 35:77–82. DOI: 10.1080/003655200750024579. PMID: 10672839.

46. Fernández-Esparrach G, Ginès A, Sánchez M, Pagés M, Pellisé M, Fernández-Cruz L, et al. 2007; Comparison of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in the diagnosis of pancreatobiliary diseases: a prospective study. Am J Gastroenterol. 102:1632–1639. DOI: 10.1111/j.1572-0241.2007.01333.x. PMID: 17521400.

47. Sai JK, Suyama M, Kubokawa Y, Watanabe S, Maehara T. 2009; Early detection of extrahepatic bile-duct carcinomas in the nonicteric stage by using MRCP followed by EUS. Gastrointest Endosc. 70:29–36. DOI: 10.1016/j.gie.2008.10.036. PMID: 19286177.

48. Heinzow HS, Kammerer S, Rammes C, Wessling J, Domagk D, Meister T. 2014; Comparative analysis of ERCP, IDUS, EUS and CT in predicting malignant bile duct strictures. World J Gastroenterol. 20:10495–10503. DOI: 10.3748/wjg.v20.i30.10495. PMID: 25132767. PMCID: PMC4130858.

49. Sotoudehmanesh R, Nejati N, Farsinejad M, Kolahdoozan S. 2016; Efficacy of endoscopic ultrasonography in evaluation of undetermined etiology of common bile duct dilatation on abdominal ultrasonography. Middle East J Dig Dis. 8:267–272. DOI: 10.15171/mejdd.2016.35. PMID: 27957289. PMCID: PMC5145293.

50. Malik S, Kaushik N, Khalid A, Bauer K, Brody D, Slivka A, et al. 2007; EUS yield in evaluating biliary dilatation in patients with normal serum liver enzymes. Dig Dis Sci. 52:508–512. DOI: 10.1007/s10620-006-9582-6. PMID: 17211694.

51. Saifuku Y, Yamagata M, Koike T, Hitomi G, Kanke K, Watanabe H, et al. 2010; Endoscopic ultrasonography can diagnose distal biliary strictures without a mass on computed tomography. World J Gastroenterol. 16:237–244. DOI: 10.3748/wjg.v16.i2.237. PMID: 20066744. PMCID: PMC2806563.

52. Tamada K, Ushio J, Sugano K. 2011; Endoscopic diagnosis of extrahepatic bile duct carcinoma: advances and current limitations. World J Clin Oncol. 2:203–216. DOI: 10.5306/wjco.v2.i5.203. PMID: 21611097. PMCID: PMC3100496.

53. Fritscher-Ravens A, Broering DC, Knoefel WT, Rogiers X, Swain P, Thonke F, et al. 2004; EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol. 99:45–51. DOI: 10.1046/j.1572-0241.2003.04006.x. PMID: 14687140.

54. Eloubeidi MA, Chen VK, Jhala NC, Eltoum IE, Jhala D, Chhieng DC, et al. 2004; Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol. 2:209–213. DOI: 10.1016/S1542-3565(04)00005-9. PMID: 15017604.

55. Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, et al. 2014; EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study. Gastrointest Endosc. 80:97–104. DOI: 10.1016/j.gie.2013.12.031. PMID: 24559784.

56. Dewitt J, Misra VL, Leblanc JK, Mchenry L, Sherman S. 2006; EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc. 64:325–333. DOI: 10.1016/j.gie.2005.11.064. PMID: 16923477.

57. Navaneethan U, Njei B, Venkatesh PG, Lourdusamy V, Sanaka MR. 2015; Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf). 3:209–215. DOI: 10.1093/gastro/gou057. PMID: 25169922. PMCID: PMC4527262.

58. Tamada K, Kanai N, Tomiyama T, Ohashi A, Wada S, Satoh Y, et al. 1999; Prediction of the histologic type of bile duct cancer by using intraductal ultrasonography. Abdom Imaging. 24:484–490. DOI: 10.1007/s002619900545. PMID: 10475933.

59. Tamada K, Nagai H, Yasuda Y, Tomiyama T, Ohashi A, Wada S, et al. 2001; Transpapillary intraductal US prior to biliary drainage in the assessment of longitudinal spread of extrahepatic bile duct carcinoma. Gastrointest Endosc. 53:300–307. DOI: 10.1016/S0016-5107(01)70402-6. PMID: 11231387.

60. Domagk D, Poremba C, Dietl KH, Senninger N, Heinecke A, Domschke W, et al. 2002; Endoscopic transpapillary biopsies and intraductal ultrasonography in the diagnostics of bile duct strictures: a prospective study. Gut. 51:240–244. DOI: 10.1136/gut.51.2.240. PMID: 12117887. PMCID: PMC1773306.

61. Farrell RJ, Agarwal B, Brandwein SL, Underhill J, Chuttani R, Pleskow DK. 2002; Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc. 56:681–687. DOI: 10.1016/S0016-5107(02)70117-X. PMID: 12397276.

62. Nakai Y, Isayama H, Tsujino T, Kawabe T, Yashima Y, Yagioka H, et al. 2008; Intraductal US in the assessment of tumor involvement to the orifice of the cystic duct by malignant biliary obstruction. Gastrointest Endosc. 68:78–83. DOI: 10.1016/j.gie.2007.12.063. PMID: 18402956.

63. Kim HM, Park JY, Kim KS, Park MS, Kim MJ, Park YN, et al. 2010; Intraductal ultrasonography combined with percutaneous transhepatic cholangioscopy for the preoperative evaluation of longitudinal tumor extent in hilar cholangiocarcinoma. J Gastroenterol Hepatol. 25:286–292. DOI: 10.1111/j.1440-1746.2009.05944.x. PMID: 19780880.

64. Choi ER, Chung YH, Lee JK, Lee KT, Lee KH, Choi DW, et al. 2011; Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography. J Gastroenterol Hepatol. 26:1804–1810. DOI: 10.1111/j.1440-1746.2011.06804.x. PMID: 21649729.

65. Meister T, Heinzow HS, Woestmeyer C, Lenz P, Menzel J, Kucharzik T, et al. 2013; Intraductal ultrasound substantiates diagnostics of bile duct strictures of uncertain etiology. World J Gastroenterol. 19:874–881. DOI: 10.3748/wjg.v19.i6.874. PMID: 23430958. PMCID: PMC3574884.

66. Vazquez-Sequeiros E, Baron TH, Clain JE, Gostout CJ, Norton ID, Petersen BT, et al. 2002; Evaluation of indeterminate bile duct strictures by intraductal US. Gastrointest Endosc. 56:372–379. DOI: 10.1016/S0016-5107(02)70041-2. PMID: 12196775.

67. Moon JH, Ko BM, Choi HJ, Hong SJ, Cheon YK, Cho YD, et al. 2009; Intraductal balloon-guided direct peroral cholangioscopy with an ultraslim upper endoscope (with videos). Gastrointest Endosc. 70:297–302. DOI: 10.1016/j.gie.2008.11.019. PMID: 19394010.

68. Teng F, Tang YY, Dai JL, Li Y, Chen ZY. 2020; The effect and safety of preoperative biliary drainage in patients with hilar cholangiocarcinoma: an updated meta-analysis. World J Surg Oncol. 18:174. DOI: 10.1186/s12957-020-01904-w. PMID: 32682432. PMCID: PMC7368977.

69. Mehrabi A, Khajeh E, Ghamarnejad O, Nikdad M, Chang DH, Büchler MW, et al. 2020; Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma. Eur J Radiol. 125:108897. DOI: 10.1016/j.ejrad.2020.108897. PMID: 32114333.

70. Celotti A, Solaini L, Montori G, Coccolini F, Tognali D, Baiocchi G. 2017; Preoperative biliary drainage in hilar cholangiocarcinoma: systematic review and meta-analysis. Eur J Surg Oncol. 43:1628–1635. DOI: 10.1016/j.ejso.2017.04.001. PMID: 28477976.

71. Kimura N, Young AL, Toyoki Y, Wyatt JI, Toogood GJ, Hidalgo E, et al. 2017; Radical operation for hilar cholangiocarcinoma in comparable Eastern and Western centers: outcome analysis and prognostic factors. Surgery. 162:500–514. DOI: 10.1016/j.surg.2017.03.017. PMID: 28551378.

72. El-Hanafy E. 2010; Pre-operative biliary drainage in hilar cholangiocarcinoma, benefits and risks, single center experience. Hepatogastroenterology. 57:414–419.

73. Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, et al. 2013; Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg. 100:274–283. DOI: 10.1002/bjs.8950. PMID: 23124720.

74. Giuliante F, Ardito F, Aldrighetti L, Ferrero A, Pinna AD, De Carlis L, et al. 2021; Liver resection for perihilar cholangiocarcinoma: impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. Surgery. 170:383–389. DOI: 10.1016/j.surg.2021.01.021. PMID: 33622570.

75. Higuchi R, Yazawa T, Uemura S, Izumo W, Chaudhary RJ, Furukawa T, et al. 2017; ENBD is associated with decreased tumor dissemination compared to ptbd in perihilar cholangiocarcinoma. J Gastrointest Surg. 21:1506–1514. DOI: 10.1007/s11605-017-3492-0. PMID: 28721561.

76. Xiong JJ, Nunes QM, Huang W, Pathak S, Wei AL, Tan CL, et al. 2013; Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol. 19:8731–8739. DOI: 10.3748/wjg.v19.i46.8731. PMID: 24379593. PMCID: PMC3870521.

77. Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, Van Gulik TM. 2006; Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol. 13:872–880. DOI: 10.1245/ASO.2006.05.053. PMID: 16614876.

78. Ercolani G, Zanello M, Grazi GL, Cescon M, Ravaioli M, Del Gaudio M, et al. 2010; Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. J Hepatobiliary Pancreat Sci. 17:329–337. DOI: 10.1007/s00534-009-0249-5. PMID: 20464563.

79. Gerhards MF, Van Gulik TM, De Wit LT, Obertop H, Gouma DJ. 2000; Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma--a single center experience. Surgery. 127:395–404. DOI: 10.1067/msy.2000.104250. PMID: 10776430.

80. Ratti F, Cipriani F, Fiorentini G, Hidalgo Salinas C, Catena M, Paganelli M, et al. 2019; Management of hilum infiltrating tumors of the liver: the impact of experience and standardization on outcome. Dig Liver Dis. 51:135–141. DOI: 10.1016/j.dld.2018.07.006. PMID: 30115572.

81. Zhang XF, Beal EW, Merath K, Ethun CG, Salem A, Weber SM, et al. 2018; Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: percutaneous biliary drainage has no adverse effects on survival. J Surg Oncol. 117:1267–1277. DOI: 10.1002/jso.24945. PMID: 29205351.

82. Ferrero A, Lo Tesoriere R, Viganò L, Caggiano L, Sgotto E, Capussotti L. 2009; Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J Surg. 33:318–325. DOI: 10.1007/s00268-008-9830-3. PMID: 19020929.

83. Parks RW, Currie EJ, Madhavan KK, Garden OJ. 2000; Increased bacterobilia associated with preoperative biliary drainage in patients with hilar cholangiocarcinoma. HPB. 2:375–381. DOI: 10.1016/S1365-182X(17)30774-8.

84. Cai Y, Tang Q, Xiong X, Li F, Ye H, Song P, et al. 2017; Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: a retrospective study at a single center. Biosci Trends. 11:319–325. DOI: 10.5582/bst.2017.01107. PMID: 28529266.

85. Figueras J, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, et al. 2000; Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl. 6:786–794. DOI: 10.1053/jlts.2000.8507. PMID: 11084070.

86. Ten Hoopen-Neumann H, Gerhards MF, Van Gulik TM, Bosma A, Verbeek PC, Gouma DJ. 1999; Occurrence of implantation metastases after resection of Klatskin tumors. Dig Surg. 16:209–213. DOI: 10.1159/000018729. PMID: 10436369.

87. Kennedy TJ, Yopp A, Qin Y, Zhao B, Guo P, Liu F, et al. 2009; Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford). 11:445–451. DOI: 10.1111/j.1477-2574.2009.00090.x. PMID: 19768150. PMCID: PMC2742615.

88. Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, et al. 2012; Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg. 147:26–34. DOI: 10.1001/archsurg.2011.771. PMID: 22250108.

89. Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, Van Klaveren D, Allen PJ, et al. 2016; Postoperative mortality after liver resection for perihilar cholangiocarcinoma: development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg. 223:321–331.e1. DOI: 10.1016/j.jamcollsurg.2016.03.035. PMID: 27063572. PMCID: PMC4961586.

90. Ribero D, Zimmitti G, Aloia TA, Shindoh J, Fabio F, Amisano M, et al. 2016; Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. J Am Coll Surg. 223:87–97. DOI: 10.1016/j.jamcollsurg.2016.01.060. PMID: 27049784. PMCID: PMC4925184.

91. Song SC, Choi DW, Kow AW, Choi SH, Heo JS, Kim WS, et al. 2013; Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre. ANZ J Surg. 83:268–274. DOI: 10.1111/j.1445-2197.2012.06195.x. PMID: 22943422.

92. Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, et al. 1996; Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 223:384–394. DOI: 10.1097/00000658-199604000-00007. PMID: 8633917. PMCID: PMC1235134.

93. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. 2010; Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2:419–427. DOI: 10.4254/wjh.v2.i12.419. PMID: 21191517. PMCID: PMC3010511.

94. Mills SE, Cater D, Greenson JK, Reuter VE, Stoler MH. Sternberg's diagnostic surgical pathology. 5th ed.Lippincott Williams & Wilkins;2010.

95. Gore RM, Fulcher AS, Taylor AJ, Ghahremani GG. Gore RM, Levine MS, editors. Anomalies and anatomic variants of the gallbladder and biliary tract. Textbook of gastrointestinal radiology. 3rd ed.Elsevier;2008. p. 1403–1404. DOI: 10.1016/B978-1-4160-2332-6.50083-X.

96. Turner MA, Fulcher AS. 2001; The cystic duct: normal anatomy and disease processes. Radiographics. 21:3–22. questionnaire 288–294. DOI: 10.1148/radiographics.21.1.g01ja093. PMID: 11158640.

97. Sarawagi R, Sundar S, Gupta SK, Raghuwanshi S. 2016; Anatomical variations of cystic ducts in magnetic resonance cholangiopancreatography and clinical implications. Radiol Res Pract. 2016:3021484. DOI: 10.1155/2016/3021484. PMID: 27313891. PMCID: PMC4897729.

98. Ruys AT, Van Beem BE, Engelbrecht MR, Bipat S, Stoker J, Van Gulik TM. 2012; Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol. 85:1255–1262. DOI: 10.1259/bjr/88405305. PMID: 22919007. PMCID: PMC3487057.

99. Park HS, Lee JM, Choi JY, Lee MW, Kim HJ, Han JK, et al. 2008; Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol. 190:396–405. DOI: 10.2214/AJR.07.2310. PMID: 18212225.

100. Akamatsu N, Sugawara Y, Osada H, Okada T, Itoyama S, Komagome M, et al. 2009; Preoperative evaluation of the longitudinal spread of extrahepatic bile duct cancer using multidetector computed tomography. J Hepatobiliary Pancreat Surg. 16:216–222. DOI: 10.1007/s00534-009-0045-2. PMID: 19214370.

101. Cho ES, Park MS, Yu JS, Kim MJ, Kim KW. 2007; Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J Comput Assist Tomogr. 31:72–78. DOI: 10.1097/01.rct.0000230013.24091.8e. PMID: 17259836.

102. Han JK, Choi BI, Kim AY, An SK, Lee JW, Kim TK, et al. 2002; Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings. Radiographics. 22:173–187. DOI: 10.1148/radiographics.22.1.g02ja15173. PMID: 11796906.

103. Choi BI, Lee JM, Han JK. 2004; Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging. 29:548–557. DOI: 10.1007/s00261-004-0188-1. PMID: 15185025.

104. Park HS, Lee JM, Kim SH, Jeong JY, Kim YJ, Lee KH, et al. 2006; CT Differentiation of cholangiocarcinoma from periductal fibrosis in patients with hepatolithiasis. AJR Am J Roentgenol. 187:445–453. DOI: 10.2214/AJR.05.0247. PMID: 16861550.

105. Choi YH, Lee JM, Lee JY, Han CJ, Choi JY, Han JK, et al. 2008; Biliary malignancy: value of arterial, pancreatic, and hepatic phase imaging with multidetector-row computed tomography. J Comput Assist Tomogr. 32:362–368. DOI: 10.1097/RCT.0b013e318126c134. PMID: 18520538.

106. Park HJ, Kim SH, Jang KM, Choi SY, Lee SJ, Choi D. 2014; The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures. Eur Radiol. 24:947–958. DOI: 10.1007/s00330-014-3097-x. PMID: 24487774.

107. Park MS, Kim TK, Kim KW, Park SW, Lee JK, Kim JS, et al. 2004; Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology. 233:234–240. DOI: 10.1148/radiol.2331031446. PMID: 15333766.

108. Kim JY, Lee JM, Han JK, Kim SH, Lee JY, Choi JY, et al. 2007; Contrast-enhanced MRI combined with MR cholangiopancreatography for the evaluation of patients with biliary strictures: differentiation of malignant from benign bile duct strictures. J Magn Reson Imaging. 26:304–312. DOI: 10.1002/jmri.20973. PMID: 17623893.

109. Wang GX, Ge XD, Zhang D, Chen HL, Zhang QC, Wen L. 2021; MRCP Combined with CT promotes the differentiation of benign and malignant distal bile duct strictures. Front Oncol. 11:683869. DOI: 10.3389/fonc.2021.683869. PMID: 34595106. PMCID: PMC8476806.

110. Mittal PK, Moreno CC, Kalb B, Mittal A, Camacho JC, Maddu K, et al. 2015; Primary biliary tract malignancies: MRI spectrum and mimics with histopathological correlation. Abdom Imaging. 40:1520–1557. DOI: 10.1007/s00261-014-0300-0. PMID: 25416002.

111. Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, et al. 2011; New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 53:1363–1371. DOI: 10.1002/hep.24227. PMID: 21480336.

112. Akamatsu N, Sugawara Y, Hashimoto D. 2011; Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol. 2:94–107. DOI: 10.5306/wjco.v2.i2.94. PMID: 21603318. PMCID: PMC3095469.

113. Lee DH, Kim B, Lee ES, Kim HJ, Min JH, Lee JM, et al. 2021; Radiologic evaluation and structured reporting form for extrahepatic bile duct cancer: 2019 consensus recommendations from the korean society of abdominal radiology. Korean J Radiol. 22:41–62. DOI: 10.3348/kjr.2019.0803. PMID: 32901457. PMCID: PMC7772383.

114. Ito K, Sakamoto Y, Isayama H, Nakai Y, Watadani T, Tanaka M, et al. 2018; The impact of MDCT and endoscopic transpapillary mapping biopsy to predict longitudinal spread of extrahepatic cholangiocarcinoma. J Gastrointest Surg. 22:1528–1537. DOI: 10.1007/s11605-018-3793-y. PMID: 29766443.

115. Lee HY, Kim SH, Lee JM, Kim SW, Jang JY, Han JK, et al. 2006; Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology. 239:113–121. DOI: 10.1148/radiol.2383050419. PMID: 16467211.

116. Unno M, Okumoto T, Katayose Y, Rikiyama T, Sato A, Motoi F, et al. 2007; Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg. 14:434–440. DOI: 10.1007/s00534-006-1191-4. PMID: 17909710.

117. Masselli G, Manfredi R, Vecchioli A, Gualdi G. 2008; MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. Eur Radiol. 18:2213–2221. DOI: 10.1007/s00330-008-1004-z. PMID: 18463877.

118. Joo I, Lee JM, Yoon JH. 2018; Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology. 288:7–13. DOI: 10.1148/radiol.2018171187. PMID: 29869969.

119. Wattanasatesiri T, Sirichindakul B, Klaikaew N, Chaopathomkul B. 2013; Perihilar cholangiocarcinoma: accuracy of 16-detector-row computed tomography in evaluating tumor extension and resectability. Asian Biomed. 7:499–507.

120. Zhou Q, Guan Y, Mao L, Zhu Y, Chen J, Shi J, et al. 2018; Modification and establishment of CT criteria in preoperative assessment of portal venous invasion by hilar cholangiocarcinoma. HPB (Oxford). 20:1163–1171. DOI: 10.1016/j.hpb.2018.05.013. PMID: 30030081.

121. Zhou Q, Dong G, Zhu Q, Qiu Y, Mao L, Chen J, et al. 2021; Modification and comparison of CT criteria in the preoperative assessment of hepatic arterial invasion by hilar cholangiocarcinoma. Abdom Radiol (NY). 46:1922–1930. DOI: 10.1007/s00261-020-02849-0. PMID: 33159559.

122. Ryoo I, Lee JM, Chung YE, Park HS, Kim SH, Han JK, et al. 2010; Gadobutrol-enhanced, three-dimensional, dynamic MR imaging with MR cholangiography for the preoperative evaluation of bile duct cancer. Invest Radiol. 45:217–224. DOI: 10.1097/RLI.0b013e3181d2eeb1. PMID: 20195160.

123. Sun HY, Lee JM, Park HS, Yoon JH, Baek JH, Han JK, et al. 2013; Gadoxetic acid-enhanced MRI with MR cholangiography for the preoperative evaluation of bile duct cancer. J Magn Reson Imaging. 38:138–147. DOI: 10.1002/jmri.23957. PMID: 23281093.

124. Park MJ, Kim YK, Lim S, Rhim H, Lee WJ. 2014; Hilar cholangiocarcinoma: value of adding DW imaging to gadoxetic acid-enhanced MR imaging with MR cholangiopancreatography for preoperative evaluation. Radiology. 270:768–776. DOI: 10.1148/radiol.13130009. PMID: 24475800.

125. Xin Y, Liu Q, Zhang J, Lu J, Song X, Zhan H, et al. 2020; Hilar cholangiocarcinoma: value of high-resolution enhanced magnetic resonance imaging for preoperative evaluation. J Cancer Res Ther. 16:1634–1640. DOI: 10.4103/jcrt.JCRT_140_20. PMID: 33565510.

126. Choi JY, Lee JM, Lee JY, Kim SH, Lee MW, Han JK, et al. 2007; Assessment of hilar and extrahepatic bile duct cancer using multidetector CT: value of adding multiplanar reformations to standard axial images. Eur Radiol. 17:3130–3138. DOI: 10.1007/s00330-007-0658-2. PMID: 17486346.

127. Li H, Zeng MS, Zhou KR, Jin DY, Lou WH. 2005; Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr. 29:170–175. DOI: 10.1097/01.rct.0000155060.73107.83. PMID: 15772532.

128. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. 1997; Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 168:1439–1443. DOI: 10.2214/ajr.168.6.9168704. PMID: 9168704.

129. Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, et al. 2022; Combined vascular resection for locally advanced perihilar cholangiocarcinoma. Ann Surg. 275:382–390. DOI: 10.1097/SLA.0000000000004322. PMID: 32976284.

130. Songthamwat M, Chamadol N, Khuntikeo N, Thinkhamrop J, Koonmee S, Chaichaya N, et al. 2018; Accuracy of computerised tomography scan for the diagnosis of lymph node metastasis in cholangiocarcinoma. J Clin Diagn Res. 12:PC12–PC16. DOI: 10.7860/JCDR/2018/34033.11196.

131. Ni Q, Wang H, Zhang Y, Qian L, Chi J, Liang X, et al. 2017; MDCT assessment of resectability in hilar cholangiocarcinoma. Abdom Radiol (NY). 42:851–860. DOI: 10.1007/s00261-016-0943-0. PMID: 27770159.

132. Promsorn J, Soontrapa W, Somsap K, Chamadol N, Limpawattana P, Harisinghani M. 2019; Evaluation of the diagnostic performance of apparent diffusion coefficient (ADC) values on diffusion-weighted magnetic resonance imaging (DWI) in differentiating between benign and metastatic lymph nodes in cases of cholangiocarcinoma. Abdom Radiol (NY). 44:473–481. DOI: 10.1007/s00261-018-1742-6. PMID: 30151713.

133. Wu XP, Ni JM, Zhang ZY, Lu FQ, Li B, Jin HH, et al. 2015; Preoperative evaluation of malignant perihilar biliary obstruction: negative-contrast CT cholangiopancreatography and CT angiography versus MRCP and MR angiography. AJR Am J Roentgenol. 205:780–788. DOI: 10.2214/AJR.14.13983. PMID: 26397326.

134. Pang L, Bo X, Wang J, Wang C, Wang Y, Liu G, et al. 2021; Role of dual-time point (18)F-FDG PET/CT imaging in the primary diagnosis and staging of hilar cholangiocarcinoma. Abdom Radiol (NY). 46:4138–4147. DOI: 10.1007/s00261-021-03071-2. PMID: 33825930.

135. Lamarca A, Barriuso J, Chander A, Mcnamara MG, Hubner RA, Õreilly D, et al. 2019; (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol. 71:115–129. DOI: 10.1016/j.jhep.2019.01.038. PMID: 30797051.

136. Hu JH, Tang JH, Lin CH, Chu YY, Liu NJ. 2018; Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. J Investig Med. 66:52–61. DOI: 10.1136/jim-2017-000472. PMID: 28912249.

137. Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. 2008; Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 103:1145–1151. DOI: 10.1111/j.1572-0241.2007.01710.x. PMID: 18177454.

138. Huang X, Yang J, Li J, Xiong Y. 2020; Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: a meta-analysis. Medicine (Baltimore). 99:e20932. DOI: 10.1097/MD.0000000000020932. PMID: 32871859. PMCID: PMC7458197.

139. Noji T, Kondo S, Hirano S, Tanaka E, Suzuki O, Shichinohe T. 2008; Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer. Br J Surg. 95:92–96. DOI: 10.1002/bjs.5920. PMID: 17853509.

140. Barlow AD, Garcea G, Berry DP, Rajesh A, Patel R, Metcalfe MS, et al. 2013; Staging laparoscopy for hilar cholangiocarcinoma in 100 patients. Langenbecks Arch Surg. 398:983–988. DOI: 10.1007/s00423-013-1104-3. PMID: 23995711.

141. Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN, et al. 2007; High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg. 193:702–706. DOI: 10.1016/j.amjsurg.2006.10.024. PMID: 17512280.

142. Zhang H, Zhu J, Ke F, Weng M, Wu X, Li M, et al. 2015; Radiological imaging for assessing the respectability of hilar cholangiocarcinoma: a systematic review and meta-analysis. Biomed Res Int. 2015:497942. DOI: 10.1155/2015/497942. PMID: 26448940. PMCID: PMC4569758.

143. Choi SY, Kim YK, Min JH, Cha DI, Jeong WK, Lee WJ. 2017; The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer. Eur Radiol. 27:4383–4393. DOI: 10.1007/s00330-017-4782-3. PMID: 28342102.

144. Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, et al. 2016; A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 16:153. DOI: 10.1186/s12885-016-2174-8. PMID: 26912134. PMCID: PMC4766710.

145. Chiang NJ, Chen JS, Chen MH, Yang SH, Hsu C, Yen CJ, et al. 2017; A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer. J Clin Oncol. 35:417. DOI: 10.1200/JCO.2017.35.4_suppl.417.

146. Coombs RJ, Zeiss J, Howard JM, Thomford NR, Merrick HW. 1990; CT of the abdomen after the Whipple procedure: value in depicting postoperative anatomy, surgical complications, and tumor recurrence. AJR Am J Roentgenol. 154:1011–1014. DOI: 10.2214/ajr.154.5.2108534. PMID: 2108534.

147. Manzione L, Romano R, Germano D. 2007; Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology. 73:311–315. DOI: 10.1159/000134239. PMID: 18493158.

148. Pongmaneratanakul S, Tanasanvimon S, Pengsuparp T, Areepium N. 2017; Prevalence of CTR1 and ERCC1 polymorphisms and response of biliary tract cancer to gemcitabine-platinum chemotherapy. Asian Pac J Cancer Prev. 18:857–861.

149. Sahani DV, Hayano K, Galluzzo A, Zhu AX. 2015; Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism. AJR Am J Roentgenol. 204:776–781. DOI: 10.2214/AJR.14.13223. PMID: 25794066.

150. Wang D, Yang X, Long J, Lin J, Mao J, Xie F, et al. 2021; the efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study. Front Oncol. 11:646979. DOI: 10.3389/fonc.2021.646979. PMID: 33912461. PMCID: PMC8071846.

151. Jung SJ, Woo SM, Park HK, Lee WJ, Han MA, Han SS, et al. 2012; Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology. 83:83–90. DOI: 10.1159/000339695. PMID: 22777276.

152. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. 2016; Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27:v28–v37. DOI: 10.1093/annonc/mdw324. PMID: 27664259.

153. Kim NH, Lee SR, Kim YH, Kim HJ. 2020; Diagnostic performance and prognostic relevance of FDG positron emission tomography/computed tomography for patients with extrahepatic cholangiocarcinoma. Korean J Radiol. 21:1355–1366. DOI: 10.3348/kjr.2019.0891. PMID: 32767862. PMCID: PMC7689144.

154. Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. 2006; Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 45:43–50. DOI: 10.1016/j.jhep.2006.03.009. PMID: 16690156.

155. Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. 2002; Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 29:1047–1054. DOI: 10.1007/s00259-002-0852-z. PMID: 12173019.

156. Albazaz R, Patel CN, Chowdhury FU, Scarsbrook AF. 2013; Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours. Insights Imaging. 4:691–700. DOI: 10.1007/s13244-013-0268-2. PMID: 23884572. PMCID: PMC3781255.

157. Corvera CU, Blumgart LH, Akhurst T, Dematteo RP, D'Angelica M, Fong Y, et al. 2008; 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 206:57–65. DOI: 10.1016/j.jamcollsurg.2007.07.002. PMID: 18155569.

158. Tashiro S, Imaizumi T, Ohkawa H, Okada A, Katoh T, Kawaharada Y, et al. 2003; Pancreaticobiliary maljunction: retrospective and nationwide survey in Japan. J Hepatobiliary Pancreat Surg. 10:345–351. DOI: 10.1007/s00534-002-0741-7. PMID: 14598134.

159. Tsuchida A, Itoi T, Endo M, Kitamura K, Mukaide M, Itokawa F, et al. 2004; Pathological features and surgical outcome of pancreaticobiliary maljunction without dilatation of the extrahepatic bile duct. Oncol Rep. 11:269–276. DOI: 10.3892/or.11.2.269. PMID: 14719053.

160. Yu ZL, Zhang LJ, Fu JZ, Li J, Zhang QY, Chen FL. 2004; Anomalous pancreaticobiliary junction: image analysis and treatment principles. Hepatobiliary Pancreat Dis Int. 3:136–139.

161. Jung YS, Lee KJ, Kim H, Kim WH, Kim IG, Yoo BM, et al. 2004; Risk factor for extrahepatic bile duct cancer in patients with anomalous pancreaticobiliary ductal union. Hepatogastroenterology. 51:946–949.

162. Ohuchida J, Chijiiwa K, Hiyoshi M, Kobayashi K, Konomi H, Tanaka M. 2006; Long-term results of treatment for pancreaticobiliary maljunction without bile duct dilatation. Arch Surg. 141:1066–1070. DOI: 10.1001/archsurg.141.11.1066. PMID: 17116798.

163. Takuma K, Kamisawa T, Tabata T, Hara S, Kuruma S, Inaba Y, et al. 2012; Importance of early diagnosis of pancreaticobiliary maljunction without biliary dilatation. World J Gastroenterol. 18:3409–3414. DOI: 10.3748/wjg.v18.i26.3409. PMID: 22807610. PMCID: PMC3396193.

164. Morine Y, Shimada M, Takamatsu H, Araida T, Endo I, Kubota M, et al. 2013; Clinical features of pancreaticobiliary maljunction: update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci. 20:472–480. DOI: 10.1007/s00534-013-0606-2. PMID: 23579999.

165. Hayashi H, Beppu T, Okabe H, Kuroki H, Nakagawa S, Imai K, et al. 2015; Functional assessment versus conventional volumetric assessment in the prediction of operative outcomes after major hepatectomy. Surgery. 157:20–26. DOI: 10.1016/j.surg.2014.06.013. PMID: 25482462.

166. Olthof PB, Wiggers JK, Groot Koerkamp B, Coelen RJ, Allen PJ, Besselink MG, et al. 2017; Postoperative liver failure risk score: identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization. J Am Coll Surg. 225:387–394. DOI: 10.1016/j.jamcollsurg.2017.06.007. PMID: 28687509.

167. Olthof PB, Coelen RJS, Bennink RJ, Heger M, Lam MF, Besselink MG, et al. 2017; (99m)Tc-mebrofenin hepatobiliary scintigraphy predicts liver failure following major liver resection for perihilar cholangiocarcinoma. HPB (Oxford). 19:850–858. DOI: 10.1016/j.hpb.2017.05.007. PMID: 28687148.

168. Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, Yamaguchi J, et al. 2016; The predictive value of indocyanine green clearance in future liver remnant for posthepatectomy liver failure following hepatectomy with extrahepatic bile duct resection. World J Surg. 40:1440–1447. DOI: 10.1007/s00268-016-3441-1. PMID: 26902630.

169. Kuboki S, Furukawa K, Takayashiki T, Takano S, Miyazaki M, Ohtsuka M. 2021; Clinical implication of ICG test in major hepatectomy for biliary tract cancer. Minerva Surg. 76:202–210. DOI: 10.23736/S2724-5691.21.08580-1. PMID: 33890438.

170. Franken LC, Rassam F, Van Lienden KP, Bennink RJ, Besselink MG, Busch OR, et al. 2020; Effect of structured use of preoperative portal vein embolization on outcomes after liver resection of perihilar cholangiocarcinoma. BJS Open. 4:449–455. DOI: 10.1002/bjs5.50273. PMID: 32181590. PMCID: PMC7260406.

171. Higuchi R, Yamamoto M. 2014; Indications for portal vein embolization in perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 21:542–549. DOI: 10.1002/jhbp.77. PMID: 24520045.

172. Konishi T, Takamoto T, Hashimoto T, Makuuchi M. 2021; Is portal vein embolization safe and effective for patients with impaired liver function? J Surg Oncol. 123:1742–1749. DOI: 10.1002/jso.26447. PMID: 33657243.

173. Olthof PB, Aldrighetti L, Alikhanov R, Cescon M, Groot Koerkamp B, Jarnagin WR, et al. 2020; Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol. 27:2311–2318. DOI: 10.1245/s10434-020-08258-3. PMID: 32103419. PMCID: PMC7311501.

174. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. 2003; Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 237:208–217. DOI: 10.1097/01.SLA.0000048447.16651.7B. PMID: 12560779. PMCID: PMC1522143.

175. Hong YK, Choi SB, Lee KH, Park SW, Park YN, Choi JS, et al. 2011; The efficacy of portal vein embolization prior to right extended hemihepatectomy for hilar cholangiocellular carcinoma: a retrospective cohort study. Eur J Surg Oncol. 37:237–244. DOI: 10.1016/j.ejso.2010.12.010. PMID: 21227625.

176. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. 2002; Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 137:675–680. discussion 680–671. DOI: 10.1001/archsurg.137.6.675. PMID: 12049538.

177. Gazzaniga GM, Filauro M, Bagarolo C, Mori L. 2000; Surgery for hilar cholangiocarcinoma: an Italian experience. J Hepatobiliary Pancreat Surg. 7:122–127. DOI: 10.1007/s005340050165. PMID: 10982603.

178. Cho MS, Kim SH, Park SW, Lim JH, Choi GH, Park JS, et al. 2012; Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg. 16:1672–1679. DOI: 10.1007/s11605-012-1960-0. PMID: 22798185.

179. Kow AW, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ, et al. 2012; Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg. 36:1112–1121. DOI: 10.1007/s00268-012-1497-0. PMID: 22374541.

180. Wahab MA, Sultan AM, Salah T, Fathy O, Elebidy G, Elshobary M, et al. 2012; Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value? Hepatogastroenterology. 59:321–324. DOI: 10.5754/hge11999. PMID: 22328268.

181. Cheng QB, Yi B, Wang JH, Jiang XQ, Luo XJ, Liu C, et al. 2012; Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV. Eur J Surg Oncol. 38:1197–1203. DOI: 10.1016/j.ejso.2012.08.009. PMID: 22992326.

182. Abd Elwahab M, El Nakeeb A, El Hanafy E, Sultan AM, Elghawalby A, Askr W, et al. 2016; Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors. World J Gastrointest Surg. 8:436–443. DOI: 10.4240/wjgs.v8.i6.436. PMID: 27358676. PMCID: PMC4919711.

183. Bhutiani N, Scoggins CR, Mcmasters KM, Ethun CG, Poultsides GA, Pawlik TM, et al. 2018; The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery. 163:726–731. DOI: 10.1016/j.surg.2017.10.028. PMID: 29306541. PMCID: PMC10203819.

184. Geers J, Jaekers J, Topal H, Aerts R, Vandoren C, Vanden Boer G, et al. 2020; Predictors of survival after surgery with curative intent for perihilar cholangiocarcinoma. World J Surg Oncol. 18:286. DOI: 10.1186/s12957-020-02060-x. PMID: 33143698. PMCID: PMC7641817.

185. Birgin E, Rasbach E, Reissfelder C, Rahbari NN. 2020; A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma. Eur J Surg Oncol. 46:747–753. DOI: 10.1016/j.ejso.2020.01.023. PMID: 31987703.

186. Yang M, Li WW, Chen JH, Cui MH, Liu JL. 2021; The value of caudate lobectomy in hilar cholangiocarcinoma treatment: a meta-analysis. Medicine (Baltimore). 100:e24727. DOI: 10.1097/MD.0000000000024727. PMID: 33607815. PMCID: PMC7899860.

187. Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. 2001; Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 233:385–392. DOI: 10.1097/00000658-200103000-00013. PMID: 11224627. PMCID: PMC1421255.

188. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. 2011; Is para-aortic lymph node metastasis a contraindication for radical resection in biliary carcinoma? World J Surg. 35:1085–1093. DOI: 10.1007/s00268-011-1036-4. PMID: 21400012.

189. Hakeem AR, Marangoni G, Chapman SJ, Young RS, Nair A, Hidalgo EL, et al. 2014; Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? Eur J Gastroenterol Hepatol. 26:1047–1054. DOI: 10.1097/MEG.0000000000000162. PMID: 25051217.

190. De Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, et al. 2012; The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer. 118:4737–4747. DOI: 10.1002/cncr.27492. PMID: 22415526.

191. Dumitraşcu T, Stroescu C, Braşoveanu V, Herlea V, Ionescu M, Popescu I. 2017; Curative-intent Surgery for Perihilar Cholangiocarcinoma with and without Portal Vein Resection - a Comparative Analysis of Early and Late Outcomes. Chirurgia (Bucur). 112:308–319. DOI: 10.21614/chirurgia.112.3.308. PMID: 28675366.

192. Hoffmann K, Luible S, Goeppert B, Weiss KH, Hinz U, Büchler MW, et al. 2015; Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma. Surgery. 158:1252–1260. DOI: 10.1016/j.surg.2015.04.032. PMID: 26216010.

193. Matsuyama R, Mori R, Ota Y, Homma Y, Kumamoto T, Takeda K, et al. 2016; Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction. Ann Surg Oncol. 23:475–484. DOI: 10.1245/s10434-016-5381-2. PMID: 27387681.

194. Song GW, Lee SG, Hwang S, Kim KH, Cho YP, Ahn CS, et al. 2009; Does portal vein resection with hepatectomy improve survival in locally advanced hilar cholangiocarcinoma? Hepatogastroenterology. 56:935–942.

195. Wang ST, Shen SL, Peng BG, Hua YP, Chen B, Kuang M, et al. 2015; Combined vascular resection and analysis of prognostic factors for hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 14:626–632. DOI: 10.1016/S1499-3872(15)60025-X. PMID: 26663011.

196. Tamoto E, Hirano S, Tsuchikawa T, Tanaka E, Miyamoto M, Matsumoto J, et al. 2014; Portal vein resection using the no-touch technique with a hepatectomy for hilar cholangiocarcinoma. HPB (Oxford). 16:56–61. DOI: 10.1111/hpb.12067. PMID: 23461754. PMCID: PMC3892315.

197. She WH, Cheung TT, Ma KW, Tsang SHY, Dai WC, Chan ACY, et al. 2020; Vascular resection and reconstruction in hilar cholangiocarcinoma. ANZ J Surg. 90:1653–1659. DOI: 10.1111/ans.15969. PMID: 32458528.

198. Liu Y, Li G, Lu Z, Wang T, Yang Y, Wang X, et al. 2021; Effect of vascular resection for perihilar cholangiocarcinoma: a systematic review and meta-analysis. PeerJ. 9:e12184. DOI: 10.7717/peerj.12184. PMID: 34631316. PMCID: PMC8466000.

199. Lurje G, Bednarsch J, Czigany Z, Lurje I, Schlebusch IK, Boecker J, et al. 2019; The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 45:1468–1478. DOI: 10.1016/j.ejso.2019.04.019. PMID: 31053477.

200. Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. 2010; Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 252:115–123. DOI: 10.1097/SLA.0b013e3181e463a7. PMID: 20531001.

201. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. 2003; Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg. 238:720–727. DOI: 10.1097/01.sla.0000094437.68038.a3. PMID: 14578735. PMCID: PMC1356151.

202. Schimizzi GV, Jin LX, Davidson JTT, Krasnick BA, Ethun CG, Pawlik TM, et al. 2018; Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford). 20:332–339. DOI: 10.1016/j.hpb.2017.10.003. PMID: 29169904. PMCID: PMC5970648.

203. Yamaguchi K, Shirahane K, Nakamura M, Su D, Konomi H, Motoyama K, et al. 2005; Frozen section and permanent diagnoses of the bile duct margin in gallbladder and bile duct cancer. HPB (Oxford). 7:135–138. DOI: 10.1080/13651820510028873. PMID: 18333177. PMCID: PMC2023938.

204. Otsuka S, Ebata T, Yokoyama Y, Mizuno T, Tsukahara T, Shimoyama Y, et al. 2019; Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma. Br J Surg. 106:774–782. DOI: 10.1002/bjs.11125. PMID: 30889275.

205. Yasukawa K, Shimizu A, Motoyama H, Kubota K, Notake T, Fukushima K, et al. 2021; Impact of remnant carcinoma in situ at the ductal stump on long-term outcomes in patients with distal cholangiocarcinoma. World J Surg. 45:291–301. DOI: 10.1007/s00268-020-05799-2. PMID: 32989580.

206. Park Y, Hwang DW, Kim JH, Hong SM, Jun SY, Lee JH, et al. 2019; Prognostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection versus R0 after additional resection. J Hepatobiliary Pancreat Sci. 26:169–178. DOI: 10.1002/jhbp.619. PMID: 30849218.

207. Yoo T, Park SJ, Han SS, Kim SH, Lee SD, Kim TH, et al. 2018; Proximal resection margins: more prognostic than distal resection margins in patients undergoing hilar cholangiocarcinoma resection. Cancer Res Treat. 50:1106–1113. DOI: 10.4143/crt.2017.320. PMID: 29141394. PMCID: PMC6192907.

208. Lee JH, Hwang DW, Lee SY, Park KM, Lee YJ. 2012; The proximal margin of resected hilar cholangiocarcinoma: the effect of microscopic positive margin on long-term survival. Am Surg. 78:471–477. DOI: 10.1177/000313481207800440. PMID: 22472407.

209. Shin D, Lee S, Lee JH, Hong SM, Park SY, Yoo C, et al. 2020; Prognostic implication of high grade biliary intraepithelial neoplasia in bile duct resection margins in patients with resected perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 27:604–613. DOI: 10.1002/jhbp.800. PMID: 32639085.

210. Nakanishi Y, Kondo S, Zen Y, Yonemori A, Kubota K, Kawakami H, et al. 2010; Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci. 17:166–173. DOI: 10.1007/s00534-009-0127-1. PMID: 19521656.

211. Sasaki R, Takeda Y, Funato O, Nitta H, Kawamura H, Uesugi N, et al. 2007; Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg. 31:1788–1796. DOI: 10.1007/s00268-007-9102-7. PMID: 17647056.

212. Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. 2005; Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 103:1210–1216. DOI: 10.1002/cncr.20906. PMID: 15685618.

213. Tsukahara T, Ebata T, Shimoyama Y, Yokoyama Y, Igami T, Sugawara G, et al. 2017; Residual carcinoma in situ at the ductal stump has a negative survival effect: an analysis of early-stage cholangiocarcinomas. Ann Surg. 266:126–132. DOI: 10.1097/SLA.0000000000001944. PMID: 27501166.

214. Han IW, Jang JY, Lee KB, Kang MJ, Kwon W, Park JW, et al. 2014; Clinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin. HPB (Oxford). 16:575–581. DOI: 10.1111/hpb.12193. PMID: 24308425. PMCID: PMC4048079.

215. Higuchi R, Ota T, Araida T, Kobayashi M, Furukawa T, Yamamoto M. 2010; Prognostic relevance of ductal margins in operative resection of bile duct cancer. Surgery. 148:7–14. DOI: 10.1016/j.surg.2009.11.018. PMID: 20116818.

216. Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, et al. 2017; Relationship between the surgical margin status, prognosis, and recurrence in extrahepatic bile duct cancer patients. Langenbecks Arch Surg. 402:87–93. DOI: 10.1007/s00423-016-1491-3. PMID: 27491729.

217. Higuchi R, Yazawa T, Uemura S, Izumo W, Furukawa T, Yamamoto M. 2017; High-grade dysplasia/carcinoma in situ of the bile duct margin in patients with surgically resected node-negative perihilar cholangiocarcinoma is associated with poor survival: a retrospective study. J Hepatobiliary Pancreat Sci. 24:456–465. DOI: 10.1002/jhbp.481. PMID: 28547855.

218. Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. 2008; Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg. 32:1067–1074. DOI: 10.1007/s00268-007-9393-8. PMID: 18231828.

219. Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Onoe S. 2016; Major hepatopancreatoduodenectomy with simultaneous resection of the hepatic artery for advanced biliary cancer. Langenbecks Arch Surg. 401:471–478. DOI: 10.1007/s00423-016-1413-4. PMID: 27023217.

220. Sakamoto Y, Nara S, Kishi Y, Esaki M, Shimada K, Kokudo N, et al. 2013; Is extended hemihepatectomy plus pancreaticoduodenectomy justified for advanced bile duct cancer and gallbladder cancer? Surgery. 153:794–800. DOI: 10.1016/j.surg.2012.11.024. PMID: 23415082.

221. Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al. 2012; Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. Ann Surg. 256:297–305. DOI: 10.1097/SLA.0b013e31826029ca. PMID: 22750757.

222. Shimizu A, Motoyama H, Kubota K, Notake T, Fukushima K, Ikehara T, et al. 2021; Safety and oncological benefit of hepatopancreatoduodenectomy for advanced extrahepatic cholangiocarcinoma with horizontal tumor spread: shinshu university experience. Ann Surg Oncol. 28:2012–2025. DOI: 10.1245/s10434-020-09209-8. PMID: 33044629.

223. Wang S, Shi N, You L, Dai M, Zhao Y. 2017; Minimally invasive surgical approach versus open procedure for pancreaticoduodenectomy: a systematic review and meta-analysis. Medicine (Baltimore). 96:e8619. DOI: 10.1097/MD.0000000000008619. PMID: 29390259. PMCID: PMC5815671.

224. Kim SH, Lee B, Hwang HK, Lee JS, Han HS, Lee WJ, et al. 2022; Comparison of postoperative complications and long-term oncological outcomes in minimally invasive versus open pancreatoduodenectomy for distal cholangiocarcinoma: a propensity score-matched analysis. J Hepatobiliary Pancreat Sci. 29:329–337. DOI: 10.1002/jhbp.1067. PMID: 34717038.

225. Nickel F, Haney CM, Kowalewski KF, Probst P, Limen EF, Kalkum E, et al. 2020; Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Surg. 271:54–66. DOI: 10.1097/SLA.0000000000003309. PMID: 30973388.

226. Kamarajah SK, Gujjuri R, Bundred JR, Hilal MA, White SA. 2021; Long-term survival after minimally invasive resection versus open pancreaticoduodenectomy for periampullary cancers: a systematic review, meta-analysis and meta-regression. HPB (Oxford). 23:197–205. DOI: 10.1016/j.hpb.2020.09.023. PMID: 33077373.

227. Ma D, Wang W, Wang J, Zhang T, Jiang Z, Du G, et al. 2022; Laparoscopic versus open surgery for hilar cholangiocarcinoma: a retrospective cohort study on short-term and long-term outcomes. Surg Endosc. 36:3721–3731. DOI: 10.1007/s00464-021-08686-6. PMID: 34398281.

228. Delitto D, Luckhurst CM, Black BS, Beck JL, George TJ Jr, Sarosi GA, et al. 2016; Oncologic and perioperative outcomes following selective application of laparoscopic pancreaticoduodenectomy for periampullary malignancies. J Gastrointest Surg. 20:1343–1349. DOI: 10.1007/s11605-016-3136-9. PMID: 27142633. PMCID: PMC6033586.

229. Li J, Xiong Y, Yang G, Zhang L, Riaz M, Xu J, et al. 2021; Complete laparoscopic radical resection of hilar cholangiocarcinoma: technical aspects and long-term results from a single center. Wideochir Inne Tech Maloinwazyjne. 16:62–75. DOI: 10.5114/wiitm.2020.97363. PMID: 33786118. PMCID: PMC7991938.

230. Jingdong L, Yongfu X, Yang G, Jian X, Xujian H, Jianhua L, et al. 2021; Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients. Surg Endosc. 35:6612–6622. DOI: 10.1007/s00464-020-08161-8. PMID: 33258033.

231. Zhang Y, Dou C, Wu W, Liu J, Jin L, Hu Z, et al. 2020; Total laparoscopic versus open radical resection for hilar cholangiocarcinoma. Surg Endosc. 34:4382–4387. DOI: 10.1007/s00464-019-07211-0. PMID: 31664578.

232. Li J, Tan X, Zhang X, Zhao G, Hu M, Zhao Z, et al. 2020; Robotic radical surgery for hilar cholangiocarcinoma: a single-centre case series. Int J Med Robot. 16:e2076. DOI: 10.1002/rcs.2076. PMID: 31925864.

233. Feng F, Cao X, Liu X, Qin J, Zhang S, Li Q, et al. 2019; Laparoscopic resection for Bismuth type III and IV hilar cholangiocarcinoma: how to improve the radicality without direct palpation. J Surg Oncol. 120:1379–1385. DOI: 10.1002/jso.25739. PMID: 31691290.

234. Li J, Zhao L, Zhang J, Li Z, Li A, Wei Y, et al. 2017; Application of the laparoscopic technique in perihilar cholangiocarcinoma surgery. Int J Surg. 44:104–109. DOI: 10.1016/j.ijsu.2017.06.038. PMID: 28629770.

235. Xu Y, Wang H, Ji W, Tang M, Li H, Leng J, et al. 2016; Robotic radical resection for hilar cholangiocarcinoma: perioperative and long-term outcomes of an initial series. Surg Endosc. 30:3060–3070. DOI: 10.1007/s00464-016-4925-7. PMID: 27194255.

236. Yu H, Wu SD, Chen DX, Zhu G. 2011; Laparoscopic resection of Bismuth type I and II hilar cholangiocarcinoma: an audit of 14 cases from two institutions. Dig Surg. 28:44–49. DOI: 10.1159/000322398. PMID: 21293131.

237. Lee GI, Lee MR, Green I, Allaf M, Marohn MR. 2017; Surgeons' physical discomfort and symptoms during robotic surgery: a comprehensive ergonomic survey study. Surg Endosc. 31:1697–1706. DOI: 10.1007/s00464-016-5160-y. PMID: 27515836.

238. Deoliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. 2007; Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 245:755–762. DOI: 10.1097/01.sla.0000251366.62632.d3. PMID: 17457168. PMCID: PMC1877058.

239. Aoba T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. 2013; Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg. 257:718–725. DOI: 10.1097/SLA.0b013e3182822277. PMID: 23407295.

240. Shiraki T, Kuroda H, Takada A, Nakazato Y, Kubota K, Imai Y. 2018; Intraoperative frozen section diagnosis of bile duct margin for extrahepatic cholangiocarcinoma. World J Gastroenterol. 24:1332–1342. DOI: 10.3748/wjg.v24.i12.1332. PMID: 29599608. PMCID: PMC5871828.

241. Endo I, House MG, Klimstra DS, Gönen M, D'Angelica M, Dematteo RP, et al. 2008; Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 15:2104–2112. DOI: 10.1245/s10434-008-0003-2. PMID: 18543039.

242. Zhang XF, Squires MH 3rd, Bagante F, Ethun CG, Salem A, Weber SM, et al. 2018; The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma. Ann Surg Oncol. 25:1140–1149. DOI: 10.1245/s10434-018-6382-0. PMID: 29470820.

243. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed.Springer Cham;2017.

244. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, Mcdonald AC, et al. 2012; Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. Jama. 308:147–156. DOI: 10.1001/jama.2012.7352. PMID: 22782416.

245. Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. 2019; Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 37:658–667. DOI: 10.1200/JCO.18.00050. PMID: 30707660.

246. Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. 2018; Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 105:192–202. DOI: 10.1002/bjs.10776. PMID: 29405274.

247. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. 2019; Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20:663–673. DOI: 10.1016/S1470-2045(18)30915-X. PMID: 30922733.

248. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. 2010; Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. DOI: 10.1056/NEJMoa0908721. PMID: 20375404.

249. Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. 2022; Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1:EVIDoa2200015. DOI: 10.1056/EVIDoa2200015. PMID: 38319896.

250. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. 2023; Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet. 401:1853–1865. DOI: 10.1016/S0140-6736(23)00727-4. PMID: 37075781.

251. Gwak HK, Kim WC, Kim HJ, Park JH. 2010; Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 78:194–198. DOI: 10.1016/j.ijrobp.2009.07.003. PMID: 19910130.

252. Chang WI, Kim BH, Kang HC, Kim K, Lee KH, Oh DY, et al. 2021; The role of adjuvant chemoradiotherapy in nonhilar extrahepatic bile duct cancer: a long-term single-institution analysis. Int J Radiat Oncol Biol Phys. 111:395–404. DOI: 10.1016/j.ijrobp.2021.05.012. PMID: 34029643.

253. Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, et al. 2000; Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 46:581–587. DOI: 10.1016/S0360-3016(99)00472-1. PMID: 10701737.

254. Kobayashi S, Nagano H, Marubashi S, Takeda Y, Tanemura M, Konishi K, et al. 2009; Impact of postoperative irradiation after non-curative resection of hilar biliary cancer. J Surg Oncol. 100:657–662. DOI: 10.1002/jso.21409. PMID: 19798692.

255. Hoehn RS, Wima K, Ertel AE, Meier A, Ahmad SA, Shah SA, et al. 2015; Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Ann Surg Oncol. 22 Suppl 3:S1133–1139. DOI: 10.1245/s10434-015-4599-8. PMID: 25976862.

256. Nassour I, Mokdad AA, Porembka MR, Choti MA, Polanco PM, Mansour JC, et al. 2018; Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma: a propensity matched study. Ann Surg Oncol. 25:1193–1201. DOI: 10.1245/s10434-018-6388-7. PMID: 29488187.

257. Kamarajah SK, Bednar F, Cho CS, Nathan H. 2021; Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: a propensity-matched National Cancer Database analysis. Cancer. 127:1266–1274. DOI: 10.1002/cncr.33356. PMID: 33320344.

258. Kim K, Yu JI, Jung W, Kim TH, Seong J, Kim WC, et al. 2021; Role of adjuvant radiotherapy in extrahepatic bile duct cancer: a multicenter retrospective study (Korean Radiation Oncology Group 18-14). Eur J Cancer. 157:31–39. DOI: 10.1016/j.ejca.2021.07.045. PMID: 34474218.

259. Bonet Beltrán M, Allal AS, Gich I, Solé JM, Carrió I. 2012; Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev. 38:111–119. DOI: 10.1016/j.ctrv.2011.05.003. PMID: 21652148.

260. Shi XQ, Zhang JY, Tian H, Tang LN, Li AL. 2020; Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis. J Zhejiang Univ Sci B. 21:549–559. DOI: 10.1631/jzus.B1900691. PMID: 32633109. PMCID: PMC7383326.

261. Choi SH, Rim CH, Shin IS, Yoon WS, Koom WS, Seong J. 2021; Adjuvant radiotherapy for extrahepatic cholangiocarcinoma: a quality assessment-based meta-analysis. Liver Cancer. 10:419–432. DOI: 10.1159/000518298. PMID: 34721505. PMCID: PMC8527906.

262. Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. 1996; A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut. 39:852–855. DOI: 10.1136/gut.39.6.852. PMID: 9038668. PMCID: PMC1383458.

263. Válek V, Kysela P, Kala Z, Kiss I, Tomásek J, Petera J. 2007; Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol. 62:175–179. DOI: 10.1016/j.ejrad.2007.01.037. PMID: 17344008.

264. Jiao D, Wu G, Ren J, Han X. 2017; Study of self-expandable metallic stent placement intraluminal (125)I seed strands brachytherapy of malignant biliary obstruction. Surg Endosc. 31:4996–5005. DOI: 10.1007/s00464-017-5481-5. PMID: 28643064.

265. De Bellis M, Fogel EL, Sherman S, Watkins JL, Chappo J, Younger C, et al. 2003; Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc. 58:176–182. DOI: 10.1067/mge.2003.345. PMID: 12872082.

266. Pugliese V, Conio M, Nicolò G, Saccomanno S, Gatteschi B. 1995; Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc. 42:520–526. DOI: 10.1016/S0016-5107(95)70004-8. PMID: 8674921.

267. Yasuda I, Enya M, Moriwaki H, Tomita E, Kato T, Mukai T, et al. 2003; Diagnostic value of transpapillary biopsy using double lumen introducer for determination of mucosal extent in extrahepatic bile duct cancer. Dig Endosc. 15:200–205. DOI: 10.1046/j.1443-1661.2003.00245.x.

268. Mansfield JC, Griffin SM, Wadehra V, Matthewson K. 1997; A prospective evaluation of cytology from biliary strictures. Gut. 40:671–677. DOI: 10.1136/gut.40.5.671. PMID: 9203949. PMCID: PMC1027173.

269. Fogel EL, Debellis M, Mchenry L, Watkins JL, Chappo J, Cramer H, et al. 2006; Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. Gastrointest Endosc. 63:71–77. DOI: 10.1016/j.gie.2005.08.039. PMID: 16377319.

270. Bang JY, Navaneethan U, Hasan M, Sutton B, Hawes R, Varadarajulu S. 2020; Optimizing outcomes of single-operator cholangioscopy-guided biopsies based on a randomized trial. Clin Gastroenterol Hepatol. 18:441–448.e441. DOI: 10.1016/j.cgh.2019.07.035. PMID: 31351135.

271. Fritscher-Ravens A, Broering DC, Sriram PV, Topalidis T, Jaeckle S, Thonke F, et al. 2000; EUS-guided fine-needle aspiration cytodiagnosis of hilar cholangiocarcinoma: a case series. Gastrointest Endosc. 52:534–540. DOI: 10.1067/mge.2000.109589. PMID: 11023576.

272. Tsai CC, Mo LR, Chou CY, Han SJ, Lin RC, Kuo JY, et al. 1997; Percutaneous transhepatic transluminal forceps biopsy in obstructive jaundice. Hepatogastroenterology. 44:770–773.

273. Moon JH, Terheggen G, Choi HJ, Neuhaus H. 2013; Peroral cholangioscopy: diagnostic and therapeutic applications. Gastroenterology. 144:276–282. DOI: 10.1053/j.gastro.2012.10.045. PMID: 23127575.

274. Komanduri S, Thosani N, Abu Dayyeh BK, Aslanian HR, Enestvedt BK, Manfredi M, et al. Asge Technology Committee. 2016; Cholangiopancreatoscopy. Gastrointest Endosc. 84:209–221. DOI: 10.1016/j.gie.2016.03.013. PMID: 27236413.

275. Manta R, Frazzoni M, Conigliaro R, Maccio L, Melotti G, Dabizzi E, et al. 2013; SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions: a single-center, prospective, cohort study. Surg Endosc. 27:1569–1572. DOI: 10.1007/s00464-012-2628-2. PMID: 23233008.

276. Siddiqui AA, Mehendiratta V, Jackson W, Loren DE, Kowalski TE, Eloubeidi MA. 2012; Identification of cholangiocarcinoma by using the Spyglass Spyscope system for peroral cholangioscopy and biopsy collection. Clin Gastroenterol Hepatol. 10:466–471. quiz e448DOI: 10.1016/j.cgh.2011.12.021. PMID: 22178463.

277. Ramchandani M, Reddy DN, Gupta R, Lakhtakia S, Tandan M, Darisetty S, et al. 2011; Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study. Gastrointest Endosc. 74:511–519. DOI: 10.1016/j.gie.2011.04.034. PMID: 21737076.

278. Draganov PV, Chauhan S, Wagh MS, Gupte AR, Lin T, Hou W, et al. 2012; Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc. 75:347–353. DOI: 10.1016/j.gie.2011.09.020. PMID: 22248602.

279. Lee YN, Moon JH, Choi HJ, Kim HK, Lee HW, Lee TH, et al. 2019; Tissue acquisition for diagnosis of biliary strictures using peroral cholangioscopy or endoscopic ultrasound-guided fine-needle aspiration. Endoscopy. 51:50–59. DOI: 10.1055/a-0645-1395. PMID: 30184609.

280. Hattori M, Nagino M, Ebata T, Kato K, Okada K, Shimoyama Y. 2011; Prospective study of biliary cytology in suspected perihilar cholangiocarcinoma. Br J Surg. 98:704–709. DOI: 10.1002/bjs.7412. PMID: 21290384.

281. Tsuchiya T, Yokoyama Y, Ebata T, Igami T, Sugawara G, Kato K, et al. 2014; Randomized controlled trial on timing and number of sampling for bile aspiration cytology. J Hepatobiliary Pancreat Sci. 21:433–438. DOI: 10.1002/jhbp.61. PMID: 24353113.

282. Kylänpää L, Boyd S, Ristimäki A, Lindström O, Udd M, Halttunen J. 2016; A prospective randomised study of dense Infinity cytological brush versus regularly used brush in pancreaticobiliary malignancy. Scand J Gastroenterol. 51:590–593. DOI: 10.3109/00365521.2015.1121514. PMID: 26642244.

283. Abraham NS, Barkun JS, Barkun AN. 2002; Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc. 56:835–841. DOI: 10.1016/S0016-5107(02)70356-8. PMID: 12447294.

284. Williamsson C, Wennerblom J, Tingstedt B, Jönsson C. 2016; A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB (Oxford). 18:107–112. DOI: 10.1016/j.hpb.2015.08.009. PMID: 26776858. PMCID: PMC4750237.

285. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. 1994; Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet. 344:1655–1660. DOI: 10.1016/S0140-6736(94)90455-3. PMID: 7996958.

286. Leng JJ, Zhang N, Dong JH. 2014; Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary tract obstruction: a meta-analysis. World J Surg Oncol. 12:272. DOI: 10.1186/1477-7819-12-272. PMID: 25148939. PMCID: PMC6389255.

287. Zhao XQ, Dong JH, Jiang K, Huang XQ, Zhang WZ. 2015; Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis. Dig Endosc. 27:137–145. DOI: 10.1111/den.12320. PMID: 25040581.

288. Almadi MA, Barkun A, Martel M. 2017; Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction: a series of meta-analyses. Am J Gastroenterol. 112:260–273. DOI: 10.1038/ajg.2016.512. PMID: 27845340.

289. Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. 1992; Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 340:1488–1492. DOI: 10.1016/0140-6736(92)92752-2. PMID: 1281903.

290. Lammer J, Hausegger KA, Flückiger F, Winkelbauer FW, Wildling R, Klein GE, et al. 1996; Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology. 201:167–172. DOI: 10.1148/radiology.201.1.8816539. PMID: 8816539.

291. Soderlund C, Linder S. 2006; Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc. 63:986–995. DOI: 10.1016/j.gie.2005.11.052. PMID: 16733114.

292. Isayama H, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N, et al. 2004; A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut. 53:729–734. DOI: 10.1136/gut.2003.018945. PMID: 15082593. PMCID: PMC1774024.

293. Almadi MA, Barkun AN, Martel M. 2013; No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol. 11:27–37.e21. DOI: 10.1016/j.cgh.2012.10.019. PMID: 23103324.

294. Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. 2010; Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol. 33:97–106. DOI: 10.1007/s00270-009-9604-9. PMID: 19495871.

295. Telford JJ, Carr-Locke DL, Baron TH, Poneros JM, Bounds BC, Kelsey PB, et al. 2010; A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc. 72:907–914. DOI: 10.1016/j.gie.2010.08.021. PMID: 21034891.

296. Kullman E, Frozanpor F, Söderlund C, Linder S, Sandström P, Lindhoff-Larsson A, et al. 2010; Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc. 72:915–923. DOI: 10.1016/j.gie.2010.07.036. PMID: 21034892.

297. Saleem A, Leggett CL, Murad MH, Baron TH. 2011; Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc. 74:321–327. e321–323. DOI: 10.1016/j.gie.2011.03.1249. PMID: 21683354.

298. Kawashima H, Hashimoto S, Ohno E, Ishikawa T, Morishima T, Matsubara H, et al. 2019; Comparison of 8- and 10-mm diameter fully covered self-expandable metal stents: a multicenter prospective study in patients with distal malignant biliary obstruction. Dig Endosc. 31:439–447. DOI: 10.1111/den.13366. PMID: 30714216.

299. Lee YN, Moon JH, Choi HJ, Choi MH, Lee TH, Cha SW, et al. 2016; Effectiveness of a newly designed antireflux valve metal stent to reduce duodenobiliary reflux in patients with unresectable distal malignant biliary obstruction: a randomized, controlled pilot study (with videos). Gastrointest Endosc. 83:404–412. DOI: 10.1016/j.gie.2015.08.084. PMID: 26385187.

300. Hamada T, Nakai Y, Isayama H. 2013; Two meta-analyses with different conclusions: stent outcomes should be standardized before their integration. Clin Gastroenterol Hepatol. 11:748. DOI: 10.1016/j.cgh.2013.01.010. PMID: 23375999.

301. Isayama H, Hamada T, Yasuda I, Itoi T, Ryozawa S, Nakai Y, et al. 2015; TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc. 27:259–264. DOI: 10.1111/den.12379. PMID: 25209944.

302. De Cassan C, Bories E, Pesenti C, Caillol F, Godat S, Ratone JP, et al. 2017; Use of partially covered and uncovered metallic prosthesis for endoscopic ultrasound-guided hepaticogastrostomy: results of a retrospective monocentric study. Endosc Ultrasound. 6:329–335. DOI: 10.4103/2303-9027.209869. PMID: 28685745. PMCID: PMC5664854.

303. Khashab MA, Van Der Merwe S, Kunda R, El Zein MH, Teoh AY, Marson FP, et al. 2016; Prospective international multicenter study on endoscopic ultrasound-guided biliary drainage for patients with malignant distal biliary obstruction after failed endoscopic retrograde cholangiopancreatography. Endosc Int Open. 4:E487–496. DOI: 10.1055/s-0042-102648. PMID: 27092334. PMCID: PMC4831932.

304. Artifon EL, Aparicio D, Paione JB, Lo SK, Bordini A, Rabello C, et al. 2012; Biliary drainage in patients with unresectable, malignant obstruction where ERCP fails: endoscopic ultrasonography-guided choledochoduodenostomy versus percutaneous drainage. J Clin Gastroenterol. 46:768–774. DOI: 10.1097/MCG.0b013e31825f264c. PMID: 22810111.

305. Lee TH, Choi JH, Park Do H, Song TJ, Kim DU, Paik WH, et al. 2016; Similar efficacies of endoscopic ultrasound-guided transmural and percutaneous drainage for malignant distal biliary obstruction. Clin Gastroenterol Hepatol. 14:1011–1019.e1013. DOI: 10.1016/j.cgh.2015.12.032. PMID: 26748220.

306. Paik WH, Lee TH, Park DH, Choi JH, Kim SO, Jang S, et al. 2018; EUS-guided biliary drainage versus ercp for the primary palliation of malignant biliary obstruction: a multicenter randomized clinical trial. Am J Gastroenterol. 113:987–997. DOI: 10.1038/s41395-018-0122-8. PMID: 29961772.

307. Wagner HJ, Knyrim K, Vakil N, Klose KJ. 1993; Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy. 25:213–218. DOI: 10.1055/s-2007-1010295. PMID: 7686100.

308. Sangchan A, Kongkasame W, Pugkhem A, Jenwitheesuk K, Mairiang P. 2012; Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc. 76:93–99. DOI: 10.1016/j.gie.2012.02.048. PMID: 22595446.

309. Moole H, Dharmapuri S, Duvvuri A, Dharmapuri S, Boddireddy R, Moole V, et al. 2016; Endoscopic versus percutaneous biliary drainage in palliation of advanced malignant hilar obstruction: a meta-analysis and systematic review. Can J Gastroenterol Hepatol. 2016:4726078. DOI: 10.1155/2016/4726078. PMID: 27648439. PMCID: PMC5014937.

310. Coelen RJS, Roos E, Wiggers JK, Besselink MG, Buis CI, Busch ORC, et al. 2018; Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 3:681–690. DOI: 10.1016/S2468-1253(18)30234-6. PMID: 30122355.

311. Lee TH, Moon JH, Choi JH, Lee SH, Lee YN, Paik WH, et al. 2019; Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture. Gastrointest Endosc. 90:222–230. DOI: 10.1016/j.gie.2019.03.011. PMID: 30905729.

312. Lee TH, Kim TH, Moon JH, Lee SH, Choi HJ, Hwangbo Y, et al. 2017; Bilateral versus unilateral placement of metal stents for inoperable high-grade malignant hilar biliary strictures: a multicenter, prospective, randomized study (with video). Gastrointest Endosc. 86:817–827. DOI: 10.1016/j.gie.2017.04.037. PMID: 28479493.

313. Mocan T, Horhat A, Mois E, Graur F, Tefas C, Craciun R, et al. 2021; Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: when and how? World J Gastrointest Oncol. 13:2050–2063. DOI: 10.4251/wjgo.v13.i12.2050. PMID: 35070041. PMCID: PMC8713328.

314. Shim DJ, Gwon DI, Han K, Kim Y, Ko GY, Shin JH, et al. 2018; Percutaneous metallic stent placement for palliative management of malignant biliary hilar obstruction. Korean J Radiol. 19:597–605. DOI: 10.3348/kjr.2018.19.4.597. PMID: 29962866. PMCID: PMC6005945.

315. Fu YF, Xu YS, Shi YB, Zong RL, Cao C. 2021; Percutaneous metal stenting for malignant hilar biliary obstruction: a systematic review and meta-analysis of unilateral versus bilateral stenting. Abdom Radiol (NY). 46:749–756. DOI: 10.1007/s00261-020-02643-y. PMID: 32671439.

316. Xia MX, Pan YL, Cai XB, Wu J, Gao DJ, Ye X, et al. 2021; Comparison of endoscopic bilateral metal stent drainage with plastic stents in the palliation of unresectable hilar biliary malignant strictures: Large multicenter study. Dig Endosc. 33:179–189. DOI: 10.1111/den.13680. PMID: 32249460.

317. Kim JY, Lee SG, Kang D, Lee DK, Park JK, Lee KT, et al. 2021; The comparison of endoscopic biliary drainage in malignant hilar obstruction by cholangiocarcinoma: bilateral metal stents versus multiple plastic stents. Gut Liver. 15:922–929. DOI: 10.5009/gnl20257. PMID: 34053917. PMCID: PMC8593498.

318. Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, et al. 2011; Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci. 56:1557–1564. DOI: 10.1007/s10620-010-1550-5. PMID: 21222156.

319. Perdue DG, Freeman ML, Disario JA, Nelson DB, Fennerty MB, Lee JG, et al. 2008; Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction: a prospective multicenter observational cohort study. J Clin Gastroenterol. 42:1040–1046. DOI: 10.1097/MCG.0b013e31815853e0. PMID: 18719507.

320. Choi JH, Lee SH, You MS, Shin BS, Choi YH, Kang J, et al. 2019; Step-wise endoscopic approach to palliative bilateral biliary drainage for unresectable advanced malignant hilar obstruction. Sci Rep. 9:13207. DOI: 10.1038/s41598-019-48384-x. PMID: 31519930. PMCID: PMC6744501.

321. Iwasaki A, Kubota K, Kurita Y, Hasegawa S, Fujita Y, Kagawa K, et al. 2020; The placement of multiple plastic stents still has important roles in candidates for chemotherapy for unresectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 27:700–711. DOI: 10.1002/jhbp.804. PMID: 32786134.

322. Hakuta R, Kogure H, Nakai Y, Kawakami H, Maguchi H, Mukai T, et al. 2021; Unilateral versus bilateral endoscopic nasobiliary drainage and subsequent metal stent placement for unresectable malignant hilar obstruction: a multicenter randomized controlled trial. J Clin Med. 10:206. DOI: 10.3390/jcm10020206. PMID: 33430020. PMCID: PMC7827318.

323. Xia MX, Cai XB, Pan YL, Wu J, Gao DJ, Ye X, et al. 2020; Optimal stent placement strategy for malignant hilar biliary obstruction: a large multicenter parallel study. Gastrointest Endosc. 91:1117–1128.e1119. DOI: 10.1016/j.gie.2019.12.023. PMID: 31881205.

324. Cassani LS, Chouhan J, Chan C, Lanke G, Chen HC, Wang X, et al. 2019; Biliary decompression in perihilar cholangiocarcinoma improves survival: a single-center retrospective analysis. Dig Dis Sci. 64:561–569. DOI: 10.1007/s10620-018-5277-z. PMID: 30238201.

325. Vienne A, Hobeika E, Gouya H, Lapidus N, Fritsch J, Choury AD, et al. 2010; Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc. 72:728–735. DOI: 10.1016/j.gie.2010.06.040. PMID: 20883850.

326. Yoshida T, Hara K, Imaoka H, Hijioka S, Mizuno N, Ishihara M, et al. 2016; Benefits of side-by-side deployment of 6-mm covered self-expandable metal stents for hilar malignant biliary obstructions. J Hepatobiliary Pancreat Sci. 23:548–555. DOI: 10.1002/jhbp.372. PMID: 27345771.

327. Hong W, Chen S, Zhu Q, Chen H, Pan J, Huang Q. 2014; Bilateral stenting methods for hilar biliary obstructions. Clinics (Sao Paulo). 69:647–652. DOI: 10.6061/clinics/2014(09)12.

328. Moryoussef F, Sportes A, Leblanc S, Bachet JB, Chaussade S, Prat F. 2017; Is EUS-guided drainage a suitable alternative technique in case of proximal biliary obstruction? Therap Adv Gastroenterol. 10:537–544. DOI: 10.1177/1756283X17702614. PMID: 28804514. PMCID: PMC5484435.

329. Minaga K, Takenaka M, Kitano M, Chiba Y, Imai H, Yamao K, et al. 2017; Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. Surg Endosc. 31:4764–4772. DOI: 10.1007/s00464-017-5553-6. PMID: 28424912.

330. Kongkam P, Orprayoon T, Boonmee C, Sodarat P, Seabmuangsai O, Wachiramatharuch C, et al. 2021; ERCP plus endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage for malignant hilar biliary obstruction: a multicenter observational open-label study. Endoscopy. 53:55–62. DOI: 10.1055/a-1195-8197. PMID: 32515005.

331. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. 2020; Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21:671–684. DOI: 10.1016/S1470-2045(20)30109-1. PMID: 32203698.

332. Choi IS, Kim KH, Lee JH, Suh KJ, Kim JW, Park JH, et al. 2021; A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer. 154:288–295. DOI: 10.1016/j.ejca.2021.06.019. PMID: 34303267.

333. Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. 2020; Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 147:2190–2198. DOI: 10.1002/ijc.33013. PMID: 32359091.

334. Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. 2021; Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 22:1560–1572. DOI: 10.1016/S1470-2045(21)00486-1. PMID: 34656226.

335. Shinohara ET, Mitra N, Guo M, Metz JM. 2009; Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys. 74:1191–1198. DOI: 10.1016/j.ijrobp.2008.09.017. PMID: 19201549.

336. Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, et al. 2020; A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 6:888–894. DOI: 10.1001/jamaoncol.2020.0930. PMID: 32352498. PMCID: PMC7193528.

337. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. 2021; Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 7:1669–1677. DOI: 10.1001/jamaoncol.2021.3836. PMID: 34554208. PMCID: PMC8461552.

338. Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, et al. 2014; Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer. 50:2975–2982. DOI: 10.1016/j.ejca.2014.08.013. PMID: 25241229.

339. Pollom EL, Alagappan M, Park LS, Whittemore AS, Koong AC, Chang DT. 2017; Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med. 6:129–141. DOI: 10.1002/cam4.975. PMID: 27891822. PMCID: PMC5269698.

340. Shinohara ET, Guo M, Mitra N, Metz JM. 2010; Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 78:722–728. DOI: 10.1016/j.ijrobp.2009.08.070. PMID: 20207503.

341. Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, et al. 2017; Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: a propensity score-matched analysis. Ann Surg Oncol. 24:4001–4008. DOI: 10.1245/s10434-017-6131-9. PMID: 29043526.

342. Yi SW, Kang DR, Kim KS, Park MS, Seong J, Park JY, et al. 2014; Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. Cancer Chemother Pharmacol. 73:191–198. DOI: 10.1007/s00280-013-2340-5. PMID: 24322374.

343. Brunner TB, Blanck O, Lewitzki V, Abbasi-Senger N, Momm F, Riesterer O, et al. 2019; Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol. 132:42–47. DOI: 10.1016/j.radonc.2018.11.015. PMID: 30825968.

344. Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, et al. 2020; Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 27:1122–1129. DOI: 10.1245/s10434-019-08142-9. PMID: 31873931.

345. Koo TR, Eom KY, Kim IA, Cho JY, Yoon YS, Hwang DW, et al. 2014; Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy. Radiat Oncol J. 32:63–69. DOI: 10.3857/roj.2014.32.2.63. PMID: 25061574. PMCID: PMC4104221.

346. Zhu HD, Guo JH, Huang M, Ji JS, Xu H, Lu J, et al. 2018; Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicenter trial. J Hepatol. 68:970–977. DOI: 10.1016/j.jhep.2017.12.028. PMID: 29331343.

347. Van Geenen RC, Keyzer-Dekker CM, Van Tienhoven G, Obertop H, Gouma DJ. 2002; Pain management of patients with unresectable peripancreatic carcinoma. World J Surg. 26:715–720. DOI: 10.1007/s00268-002-6210-2. PMID: 12053225.

348. Xu X, Li J, Wu J, Zhu R, Ji W. 2018; A systematic review and meta-analysis of intraluminal brachytherapy versus stent alone in the treatment of malignant obstructive jaundice. Cardiovasc Intervent Radiol. 41:206–217. DOI: 10.1007/s00270-017-1827-6. PMID: 29075881.

349. Dowsiriroj P, Paholpak P, Sirichativapee W, Wisanuyotin T, Laupattarakasem P, Sukhonthamarn K, et al. 2017; Cholangiocarcinoma with spinal metastasis: Single center survival analysis. J Clin Neurosci. 38:43–48. DOI: 10.1016/j.jocn.2016.12.048. PMID: 28108084.